Melissa Baird - 10 Dec 2024 Form 4 Insider Report for Hims & Hers Health, Inc. (HIMS)

Role
Chief Operating Officer
Signature
/s/ Alexandra Cotter Wilkins, Attorney-in-Fact
Issuer symbol
HIMS
Transactions as of
10 Dec 2024
Net transactions value
-$2,618,905
Form type
4
Filing time
12 Dec 2024, 17:02:00 UTC
Previous filing
19 Nov 2024
Next filing
17 Dec 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction HIMS Class A Common Stock Options Exercise $34,224 +85,561 +14% $0.4000 716,547 10 Dec 2024 Direct F1
transaction HIMS Class A Common Stock Sale $802,495 -26,266 -3.7% $30.55 690,281 10 Dec 2024 Direct F1, F2, F3
transaction HIMS Class A Common Stock Sale $1,588,001 -51,082 -7.4% $31.09 639,199 10 Dec 2024 Direct F1, F4
transaction HIMS Class A Common Stock Sale $262,633 -8,213 -1.3% $31.98 630,986 10 Dec 2024 Direct F1, F5

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction HIMS Stock Option (right to buy) Options Exercise $0 -85,561 -25% $0.000000 257,617 10 Dec 2024 Class A Common Stock 85,561 $0.4000 Direct F1, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The stock option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on May 30, 2024 by the Reporting Person.
F2 Price reported constitutes the average weighted price of shares sold. Shares were sold at varying prices in the range of $29.785 - $30.78. The Reporting Person hereby undertakes, upon request of the Commission, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
F3 Includes 820 shares acquired on November 20, 2024, under the Hims & Hers Health, Inc. 2020 Employee Stock Purchase Plan.
F4 Price reported constitutes the average weighted price of shares sold. Shares were sold at varying prices in the range of $30.785 - $31.77. The Reporting Person hereby undertakes, upon request of the Commission, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
F5 Price reported constitutes the average weighted price of shares sold. Shares were sold at varying prices in the range of $31.86 - $32.265. The Reporting Person hereby undertakes, upon request of the Commission, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
F6 Prior to the Company's business combination transaction in 2021, the option represented the right to purchase 2,043,499 shares of Class A common stock of Hims, Inc., with an exercise price of $0.18. Following the Company's business combination transaction in 2021, the option converted into the right to purchase 1,086,723 shares of the Company with an exercise price of $0.40. 100% of the shares subject to the option have vested.